Zobrazeno 1 - 10
of 186
pro vyhledávání: '"Imam, Waked"'
Autor:
Gamal Esmat, Hala Zaid, Mohamed Hassany, Wael Abdel-Razek, Magdy El-Serafy, Wafaa El Akel, Aysam Salah, Ehab Kamal, Galal Elshishiney, Islam Ammar, Khaled Kabil, Mohamed AbdAllah, Ramy Saeed, Tarek Saad, Yasser Omar, Hany Dabbous, Manal H. El-Sayed, Yehia El Shazly, Wahid Doss, Imam Waked
Publikováno v:
Egyptian Liver Journal, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Obesity is a global health problem and has been increasing in Egypt over the last several decades. A national population screening program for hepatitis C included screening for obesity. Here we report the outcome of body mass index (BMI) ca
Externí odkaz:
https://doaj.org/article/15e05e44373e4f3a82c179f9968f1246
Publikováno v:
Pathogens, Vol 13, Iss 8, p 681 (2024)
Egypt has long been overwhelmed by the hepatitis C virus (HCV) infection, and it used to be the country with the world’s highest prevalence rates. The disease had been a significant public health problem, affecting millions of Egyptians and posing
Externí odkaz:
https://doaj.org/article/2af6caa782a4431d8dc8a85c252c9287
Publikováno v:
Egyptian Liver Journal, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Background Oral direct-acting antiviral (DAA) regimens for chronic hepatitis C virus (HCV) infection have greatly improved treatment efficacy, with sustained virological response (SVR) rates of > 95% for HCV monoinfected patients. However, h
Externí odkaz:
https://doaj.org/article/14282923f1d244bb9e10a0cca2058364
Publikováno v:
Annals of Hepatology, Vol 27, Iss 2, Pp 100679- (2022)
Externí odkaz:
https://doaj.org/article/fa23943efe034397b575930168c24cd6
Publikováno v:
Annals of Hepatology, Vol 19, Iss 5, Pp 541-545 (2020)
Introduction and aim: The interleukin-2 receptor antagonist; basiliximab is used to allow delayed introduction of Calcineurin inhibitors (CNI) after liver transplantation and thus delay their renal insult. However, there is only little evidence for t
Externí odkaz:
https://doaj.org/article/d8aeb29f864f48ae99c4ce2720af0d05
Publikováno v:
Egyptian Liver Journal, Vol 10, Iss 1, Pp 1-6 (2020)
Abstract Background Ascites is one of the main complications of advanced liver cirrhosis. It is defined as a pathological accumulation if free fluid in the peritoneal cavity. Main body of the abstract Ascites is a sign of decompensation in patients w
Externí odkaz:
https://doaj.org/article/45cbb9066cf046dba2bdcc8533fea707
Publikováno v:
Egyptian Liver Journal, Vol 10, Iss 1, Pp 1-8 (2020)
Abstract Background Large-volume paracentesis (LVP) is a main pillar in treating patients with tense ascites. Without plasma expanders use, paracentesis-induced circulatory dysfunction (PICD) is a common complication with decreased survival. The aim
Externí odkaz:
https://doaj.org/article/419b833073e04655ad38155ffa585337
Autor:
Heba Omar, Imam Waked, Wafaa Elakel, Rabab Salama, Wael Abdel-Razik, Hesham Elmakhzangy, Yasser Omar Abdel-Rahman, Ramy Saeed, Arwa Elshafaey, Dina H. Ziada, Sohier Ahmed Ismail, Hany M. Dabbous, Gamal Esmat
Publikováno v:
Arab Journal of Gastroenterology. 24:65-72
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f3c509b22ce0f2a445c0bafc1bad25a
https://doi.org/10.1016/j.ajg.2023.01.002
https://doi.org/10.1016/j.ajg.2023.01.002
Autor:
Mai Abozeid, Ayman Alsebaey, Eman Abdelsameea, Warda Othman, Mostafa Elhelbawy, Amr Rgab, Marwa Elfayomy, Tamer Samir Abdel-Ghafar, Mervat Abdelkareem, Alyaa Sabry, Marwa Fekry, Nashwa Shebl, Eman Rewisha, Imam Waked
Publikováno v:
International Journal of Infectious Diseases, Vol 75, Iss , Pp 109-114 (2018)
Background: Direct acting antivirals (DAAs) are highly effective for treatment of hepatitis C (HCV) but brand products are priced beyond the means of most low and middle income countries (LMICs). Although a few DAAs are offered at reduced prices in a
Externí odkaz:
https://doaj.org/article/f2f01efc131844baa47f7ea5d2c39b90
Autor:
Dina Attia, Shereen Abdel Alem, Wafaa El‐Akel, Wael Abdel‐Razek, Mohamed Eslam, Yasser Fouad, Imam Waked
Publikováno v:
Alimentary Pharmacology & Therapeutics. 56:1581-1590
Metabolic-associated fatty liver disease (MAFLD) was proposed in 2020 to identify fatty liver disease associated with metabolic risks. Metabolic abnormalities with hepatitis C virus (HCV) and MAFLD frequently co-exist. However, data on the co-existen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::434501fe0a5974edacf0ed2b8c97fc28
https://doi.org/10.1111/apt.17233
https://doi.org/10.1111/apt.17233